Let's get right to it.
A lot of investors might like Kroger (KR) - Get Kroger Co. (KR) Report at this level, as it fell 9.41% to $25.76 a share Thursday, after missing earnings estimates and issuing weak earnings per share guidance. But the stock still has its troubles ahead.
First, let's get to what happened, in case you missed it. Kroger missed earnings estimates, posting EPS of 48 cents, lower than Wall Street's expected 52 cents. Management guided for EPS in the full year of 2019 of between $2.15 to $2.25, below analysts hopes for $2.26. Go in now after the stock fell, right?
Wrong, says Senior Portfolio Analyst for Jim Cramer's Action Alerts Plus, Jeff Marks. There isn't much upside, as Walmart (WMT) - Get Walmart Inc. Report and Amazon (AMZN) - Get Amazon.com, Inc. Report have stepped solidly into the grocery space. "Walmart is doing too much disruption in the industry," Marks said. Walmart reported earnings in February and posted e-commerce sales growth of 43% year-over-year in its latest quarter. It doesn't break out grocery sales, but much of Walmart's grocery business is centered on online sales, with app purcahses and pickup options potentially proliferating in the near future.
Plus, Kroger doesn't offer a dividend yield premium to Walmart's. Kroger's is 2.19%, versus Walmart's 2.18%.
Allergan (AGN) - Get Allergan plc Report has certainly had its troubles in the past few years, and in the early going in 2019. With the stock up 5% Thursday as the Food and Drug Administration accepted licenses for two new botox products. But with hedge fund activist David Tepper looking to replace the current CEO and Chairman Brenton Saunders, and several failed attempts at growth, such as the merger that never was with Pfizer (PFE) - Get Pfizer Inc. Report , Marks likes other names in pharmaceuticals. "If I'm looking for a pharmaceutical company, why not Johnson & Johnson (JNJ) - Get Johnson & Johnson (JNJ) Report ?" he said.
Related.Johnson and Johnson, an AAP holding just scored a big win with the FDA, which Jim Cramer likes for the stock.
Related. How Tepper may actually find success in his attempt to remove Saunders from one of his roles at Allergan.